9th Biennial CBMTG Conference
300 delegates from Canada and around the world attended the 9th Biennial CBMTG Conference held from June 3 - 6, 2004 in beautiful London, Ontario.
The 9th Biennial CBMTG Conference was made possible thanks to unrestricted educational grants from:
AMGEN Canada Inc.
Novartis
Ortho Biotech
Hoffmann-La Roche Limited
Merck Frosst Canada Ltd.
Fujisawa Canada Inc.
Pfizer Canada Inc.
Gambro Inc.
THERAKOS, a Johnson & Johnson Company
Enzon Pharmaceuticals
Genzyme Canada Inc.
Miltenyi Biotec, Inc.
StemSoft Software Inc.
ESP Pharma
Genesis Bio-Pharmaceuticals
Program
Pre-Conference Sessions
Wednesday, June 2, 2004
8:00 am –12:00 noon FACT Workshop
1:00 pm – 10:00 pm CBMTG Clinical Trials Network Meeting
Day One
Thursday, June 3, 2004
7:30 am Breakfast
8:30 am Welcome
Session I Quality of Life in HSCT
8:45 am The Gift of Life Comes with a Price
John Wingard
9:25 am Illness Intrusiveness and Quality of Life in BMT
Gerald Devins
10:20 am Break
Session II Concurrent Sessions
10:35 am Session A: Laboratory Issues
CBMTG Technologist Committee Update
Mike Halpenny
ISCT Lab Practices Committee
Speaker TBA
Stem Cell Laboratory Technologist-reclassification
Patty Bakkestad-Legare
Open Discussion Session B: Infection
Infection Control in BMT Recipients – hospital and home
Fiona Smaill
The Diagnosis and Management of Central Venous Line Infections
Bill Thompson
West Nile Virus
Speaker TBA
12:00 noon Lunch
Session III Late Effects of HSCT
1:30 pm Psychological Effects of SCT and Practical Approaches to Therapy/Intervention
Mary Elliot
2:15 pm Exercise in post BMT fatigue
James Russell
3:00 pm Break
3:10 pm Late Effects and Quality of Adult Life After Pediatric Marrow Transplantation
Jean Sanders
4:45 pm Executive & Sponsor Reception
(Board of Directors, Executive Committee, Advisory Board, Conference Sponsors and Supporters)
Day Two
Friday, June 4, 2004
7:30 am Breakfast
Session V Concurrent Sessions
9 :00 am
9:25 am
9:50 am Session A: Myeloma
Overview of Transplantation in Multiple Myeloma
Keith Stewart
Multiple myeloma and allogeneic transplantation:where do we stand
Jean Roy
Speaker TBA
Session B: Non-Malignant Indications (Pediatric)
Stem Cell Transplantation in Children with Hemophagocytic Lymphohistiocytosis (HLH): Results of the HLH-94 Study
Jan-Inge Henter
Mesenchymal Stem Cell Transplantation for Skeletal Disorders
Edwin Horwitz
Transplantation & Gene Therapy for Immune Disorders
Marina Cavazzana-Calvo
10:20 am Break
Session VI Cord Blood and Mesenchymal Stem Cells
10:30 am – 12:00 noon Speakers TBA
12:00 noon Lunch
Session VII Stem Cell Plasticity
2:00 pm – 3:20 pm Speakers TBA
3:20 pm Break
Session VIII Research, Education & Program Development Presentations
3:30 pm – 4:30 pm Presentations from selected abstracts
Session IX Poster Presentations
4:30 pm
Day Three
Saturday, June 5, 2004
7:30 am Breakfast
Session X Non-Hodgkin’s Lymphoma and Immunotherapy
9:00 am Ralph Meyer
9:30 am – 10:20 am Speakers TBA
10:20 am Break
Session XI Transplantation of Hodgkin’s Lymphoma
10:35 am Results from Autologous Transplantation
Donna Hogge
11:10 am Allogeneic Transplantion
James Russell
11:45 am Lunch
Session XII Graft versus Host Disease and HLA Typing
1:30 pm – 2:50 pm Speakers TBA
2:50 pm Break
Session XIII Acute Leukemia, Meta-Analysis of Bone Marrow vs. Peripheral Blood Allogeneic Trials
3:05 pm – 4:25 pm Speakers TBA
4:25 pm Closing remarks
Kang Howson-Jan and Irwin Walker
5:00 pm CBMTG Annual Business Meeting
7:00 pm Gala Dinner